$2.94 Billion is the total value of ARMISTICE CAPITAL, LLC's 106 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | SPDR S&P 500 ETF TRput | $411,268,000 | +11.6% | 11,000 | 0.0% | 13.99% | +4.7% | |
| CPRX | CATALYST PHARMACEUTICALS INC | $33,400,000 | +12.5% | 10,000,000 | 0.0% | 1.14% | +5.5% | |
| ADMS | ADAMAS PHARMACEUTICALS INC | $11,873,000 | +5.1% | 2,742,000 | 0.0% | 0.40% | -1.5% | |
| EYEG | EYEGATE PHARMACEUTICALS INC | $8,950,000 | +25.8% | 1,815,500 | 0.0% | 0.30% | +17.8% | |
| TENAX THERAPEUTICS INC | $3,757,000 | +20.8% | 2,019,995 | 0.0% | 0.13% | +13.3% | ||
| SYTAW | SIYATA MOBILE INC*w exp 09/24/202 | $1,268,000 | +161.4% | 150,000 | 0.0% | 0.04% | +138.9% | |
| NERV | MINERVA NEUROSCIENCES INC | $1,170,000 | -26.4% | 500,000 | 0.0% | 0.04% | -31.0% | |
| KBNTW | KUBIENT INC*w exp 07/09/202 | $1,108,000 | +201.9% | 275,000 | 0.0% | 0.04% | +192.3% | |
| MDGSW | MEDIGUS LTD*w exp 07/23/202 | $1,095,000 | +72.7% | 1,285,715 | 0.0% | 0.04% | +60.9% | |
| GOVXW | GEOVAX LABS INC*w exp 09/29/202 | $887,000 | +5.0% | 391,700 | 0.0% | 0.03% | -3.2% | |
| VXRT | VAXART INC | $831,000 | -14.2% | 145,523 | 0.0% | 0.03% | -20.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC | 30 | Q3 2023 | 2.7% |
| SPDR S&P 500 ETF TR | 28 | Q3 2023 | 29.5% |
| MADRIGAL PHARMACEUTICALS INC | 27 | Q3 2023 | 2.9% |
| VANDA PHARMACEUTICALS INC | 26 | Q3 2021 | 9.4% |
| REGENERON PHARMACEUTICALS | 25 | Q3 2023 | 3.2% |
| ENERGIZER HLDGS INC NEW | 22 | Q2 2023 | 3.7% |
| ANTARES PHARMA INC | 21 | Q3 2020 | 6.6% |
| INCYTE CORP | 21 | Q3 2023 | 2.8% |
| VOYAGER THERAPEUTICS INC | 21 | Q3 2023 | 2.0% |
| BLUEBIRD BIO INC | 20 | Q4 2021 | 1.8% |
View ARMISTICE CAPITAL, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Avalo Therapeutics, Inc. | June 28, 2023 | 588,850 | 4.7% |
| Addex Therapeutics Ltd. | February 16, 2023 | 675,295 | 5.0% |
| Arcadia Biosciences, Inc. | February 14, 2023 | 2,675,409 | 10.0% |
| Avinger Inc | February 14, 2023 | 789,400 | 10.0% |
| Baudax Bio, Inc. | February 14, 2023 | 1,165,709 | 5.0% |
| BIORA THERAPEUTICS, INC. | February 14, 2023 | 12,989,648 | 5.7% |
| Bit Digital, Inc | February 14, 2023 | 3,161,889 | 3.7% |
| Bruush Oral Care Inc. | February 14, 2023 | 1,122,922 | 10.0% |
| CATALYST PHARMACEUTICALS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| Clarus Therapeutics Holdings, Inc. | February 14, 2023 | 2,732,169 | 5.0% |
View ARMISTICE CAPITAL, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View ARMISTICE CAPITAL, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.